Exelixis Inc. buy klostergang
Start price
29.01.19
/
50%
€20.91
Target price
04.11.21
€35.18
Performance (%)
-11.66%
End price
17.06.21
€18.47
Summary
This prediction ended on 17.06.21 with a price of €18.47. The prediction for Exelixis Inc. disappointed with a performance of -11.66%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Exelixis Inc. | 0.838% | 0.838% | 6.456% | 114.634% |
| iShares Core DAX® | -1,10 % | -6,08 % | 0,87 % | 54,49 % |
| iShares Nasdaq 100 | 0,33 % | 2,33 % | 18,26 % | 85,55 % |
| iShares Nikkei 225® | -1,08 % | -7,99 % | 26,34 % | 55,41 % |
| iShares S&P 500 | -0,06 % | 0,88 % | 13,29 % | 62,99 % |
Comments by klostergang for this prediction
In the thread Exelixis Inc. diskutieren
klostergang stimmt der Buy-Einschätzung von stratec zu
klostergang stimmt am 29.01.2018 der Buy-Einschätzung von stratec mit dem Kursziel 34$ zu.
Überschrift: EXEL is currently becoming a key player in the kidney cancer space
Update:
The stock sold off after fourth-quarter earnings, but the long-term thesis appears intact as label expansion for cabozantinib and other bullish drivers should kick in in the medium term. Near-term weakness, long-term outperformance is my initial impression.